AR
ZNTL icon

Advisory Research’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Advisory Research’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-19,770
Closed -$1.66M – 442
2021
Q4 		$1.66M Buy
19,770
+2,480
+14% +$192K 0.13% 137
2021
Q3 		$1.15M Buy
+17,290
New +$997K 0.07% 182

Other funds holding ZNTL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Advisory Research's ZNTL Position: Q1 2022 in Review

Advisory Research sold out of Zentalis Pharmaceuticals (ZNTL) in Q1 2022, closing a stake of 19,770 shares — an estimated $1.66M sold.

Advisory Research first reported a position in ZNTL in Q3 2021 and held it in 2 quarters. The position peaked at $1.66M in Q4 2021. 128 funds tracked by Wall St. Rank hold ZNTL as of Q1 2022.

  • Advisory Research reported no remaining Zentalis Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Advisory Research sold 19,770 Zentalis Pharmaceuticals shares in Q1 2022, an estimated $1.66M.
  • Advisory Research first reported a position in Zentalis Pharmaceuticals in Q3 2021 and held it in 2 quarters.
  • Advisory Research's Zentalis Pharmaceuticals position peaked at $1.66M in Q4 2021.
  • 128 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2022.

Based on Advisory Research's 13F filing for Q1 2022, filed 16 May 2022.